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Atypical/Nor98 scrapie (AS) is a prion disease of small ruminants.
Currently there are no efficient measures to control this form of
prion disease, and, importantly, the zoonotic potential and the risk
that AS might represent for other farmed animal species remains
largely unknown. In this study, we investigated the capacity of AS to
propagate in bovine PrP transgenic mice. Unexpectedly, the trans-
mission of AS isolates originating from 5 different European coun-
tries to bovine PrP mice resulted in the propagation of the classical
BSE (c-BSE) agent. Detection of prion seeding activity in vitro by
protein misfolding cyclic amplification (PMCA) demonstrated that
low levels of the c-BSE agent were present in the original AS isolates.
C-BSE prion seeding activity was also detected in brain tissue of
ovine PrP mice inoculated with limiting dilutions (endpoint titration)
of ovine AS isolates. These results are consistent with the emergence
and replication of c-BSE prions during the in vivo propagation of AS
isolates in the natural host. These data also indicate that c-BSE
prions, a known zonotic agent in humans, can emerge as a dominant
prion strain during passage of AS between different species. These
findings provide an unprecedented insight into the evolution of
mammalian prion strain properties triggered by intra- and interspe-
cies passage. From a public health perspective, the presence of c-BSE
in AS isolates suggest that cattle exposure to small ruminant tissues
and products could lead to new occurrences of c-BSE.
prion | atypical scrapie | c-BSE
Transmissible spongiform encephalopathies (TSEs), or priondiseases, are fatal neurodegenerative disorders that affect a
large spectrum of mammalian species. These conditions include
scrapie in small ruminants, classical bovine spongiform enceph-
alopathy (c-BSE) in cattle, and sporadic Creutzfeldt–Jakob dis-
ease (sCJD) or variant CJD (vCJD) in humans.
The fundamental event in prion propagation is the conversion of
the normal cellular prion protein (PrPC) into an abnormal disease-
associated isoform (PrPSc) in tissues of infected individuals. PrPC is
completely degraded by digestion with proteinase K (PK), whereas
PrPSc is N-terminally truncated, resulting in a PK-resistant core
termed PrPres (1). According to the prion concept, PrPSc is the
principal, if not sole, component of the transmissible prion agent (2),
and PrPres is a disease marker for prion diseases (1, 3). Particular
biochemical properties of PrPSc, such as detergent solubility, PK
resistance, and electromobility evidenced by Western blot can be
used to distinguish between different prion agents or strains (4, 5).
Intraspecies transmission of prion disease between individuals
is typically quite efficient. In contrast, interspecies transmission
of prions can be unpredictable, with apparent failure of disease
transmission on many occasions. In other cases, clinical prion
disease may not be evident but, rather, there is the presence of
subclinical infection (6). When interspecies prion transmission
does occur, the propagating agent can remain identical to the
original prion strain or can display different biological properties
compared to the original inoculum (7, 8). This complex set of
outcomes for interspecies prion challenge are collectively referred
to as the transmission barrier phenomenon.
After identification of the gene encoding PrP, it was soon dis-
covered that differences in amino acid sequence between host
PrPC and donor PrPSc constitutes the principal determinant of the
transmission barrier. For example, the resistance of wild-type mice
to clinical prion disease induced by hamster scrapie is abrogated
by transgenic expression of hamster PrPC in mice (9, 10). As a
consequence, mice genetically engineered to express particular
species forms of PrP sequence, in the absence of endogenous
mouse PrP, have emerged as relevant models to experimentally
characterize the outcome of prion strain transmission between
species (11). It is also now well established that strain properties
have a significant impact on the ability of prions to cross the
species barrier. For instance, human vCJD can be transmitted
readily to conventional mice, but it is extremely difficult for sCJD
to propagate in the same mouse lines (12, 13). Furthermore, the
amino acid sequence of PrPSc influences the efficacy of interspecies
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prion transmissions, since studies in human PrP transgenic mouse
models indicate that the human species barrier is more permeable
to sheep-passaged BSE compared to its cattle counterpart (14).
From a public health perspective, the transmission barrier phe-
nomenon and its capacity to limit the interspecies propagation of
prion disease has long been considered as an effective protection of
humans against animal TSEs (15). However, in 1996, the new hu-
man prion disease vCJD was observed in people in the United
Kingdom. Multiple lines of evidence indicated that vCJD was the
likely consequence of dietary exposure of humans to the agent
responsible for c-BSE in cattle, an epizootic prion disease that has
spread in bovine hosts through the recycling of prion-contaminated
animal carcasses in the animal food chain (16). Since the emer-
gence of vCJD, considerable efforts have been deployed to char-
acterize not only the zoonotic potential of animal prions but also
their capacity to propagate in farmed animal species.
Atypical/Nor98 scrapie (AS) probably represents the largest
geographically spread known animal prion disease. Since its original
discovery in 1998 in Norway, AS has been identified in most EU
member states, in Asia, and in North and South America (17). AS
has also been detected in Australia and New Zealand, 2 countries
that were believed to be free of animal TSEs (18, 19). Retrospective
studies carried out in archived animal tissues identified an AS case
in a sheep that died in 1972 in the United Kingdom, demonstrating
that the disease has been present in small ruminant populations for
many decades (20).
Bioassay in ovine PrP transgenic mice provided evidence that AS
comprised a single prion strain (21–23). The AS prion strain was as-
sociated with a multiband PrPres signature that contrasted with those
normally observed in small ruminant TSE cases (24). Since there is no
statistical difference in the apparent prevalence of atypical scrapie
between sheep flocks in general and those flocks where a positive case
had been identified, atypical scrapie is considered by many as a
noncontagious prion disease that arises sporadically in sheep and
goats (25). However, atypical scrapie can be experimentally
transmitted via the oral route in small ruminants, resulting in a
similar clinicopathological phenotype to that observed in natural
cases (26). Consequently, the origin of atypical scrapie (sponta-
neous disorder versus acquired disease) remains an open question.
In this study, we used mice transgenic for bovine PrP (tgBov
mouse line) to characterize the capacity of sheep AS isolates to cross
the bovine transmission barrier. Unexpectedly, the TSE agent that
propagated in tgBov mice was indistinguishable from the prion strain
that was responsible for the c-BSE epizootic in cattle. In addition,
our sensitive detection of c-BSE by in vitro PMCA methodology
indicated that this bovine prion strain was present as a minor prion
strain in the original sheep AS isolates, and that AS prion strain
replication in an ovine PrP host was accompanied by the generation
of c-BSE prions. Collectively, these data provide compelling evidence
for the emergence and the propagation of zoonotic mammalian
prions during intra- and interhost transmission of the AS prion strain.
Results
A panel of 8 atypical scrapie (AS) cases collected from sheep and
goats in 5 different European countries was obtained (Table 1).
All of the AS isolates displayed a multiband abnormal PrP
(PrPres) Western blot profile that was considered to be specific
for small ruminant AS (SI Appendix, Fig. S1). This panel of AS
isolates was transmitted to the VRQ ovine PrP transgenic mice
(tg338). The transmission properties such as incubation period
(SI Appendix, Table S1), vacuolar lesion profile (Fig. 1A), and
PrPres Western blot profile in the brain (SI Appendix, Fig. S1) of
the propagated AS isolates observed after 2 or 3 iterative pas-
sages in tg338 were similar and were the same as previously
reported for AS passage in tg338 mice (21–23).
The panel of 8 AS isolates was individually serially transmitted
(2 or 3 iterative passages) in bovine PrP transgenic mice (tgBov;
Table 1). On first passage, signs of clinical prion disease were
observed in a low proportion of inoculated tgBov mice. PrPres was
detected by Western blot in the brains of clinically affected mice
and in some mice that displayed no apparent clinical signs of prion
disease when euthanized at the end of their life expectancy. No
PrPres accumulation was observed in tgBov mice after inoculation
with several of the AS isolates (AS 2, AS 3, AS 5, AS 6, and AS 7),
as was the case with classical scrapie PS42 (Table 1).
Table 1. Inoculation of atypical scrapie isolates in bovine PrP (tgBov) expressing mice
Isolates
TgBov
First passage Second passage Third passage
Identifiant Origin Genotype
Positive
mice
Incubation,
mean ± SD
Positive
mice
Incubation,
mean ± SD
Positive
mice
Incubation,
mean ± SD
AS 1 Fr ARQ*/ARQ 1/6 533 3/5 317 ± 63 7/7 235 ± 16
AS 2 Sp ARR/ARQ 0/6 >650 7/9 354 ± 26 5/5 273 ± 5
AS 3 Sp ARQ/ARH 0/6 >650 2/11 504, 525‡ 12/12 269 ± 13
AS 4 Nor ARQ*/ARQ* 3/4 395 ± 44 6/6 230 ± 17 6/6 271 ± 18
AS 5 Sp ARQ/ARQ 0/6 >650 0/4 >650 NA —
AS 6 Sp ARQ/ARH 0/6 >650 1/4 >650‡ NA —
AS 7† It ARQ/AHQ 0/6 >650 1/7 424 6/6 286 ± 14
AS 8 Po ARQ/ARQ 1/5 439 5/5 297 ± 14 6/6 250 ± 4
PS42 Fr VRQ/VRQ 0/6 >650 0/6 >650 0/6 >650
Ovine c-BSE Fr ARQ/ARQ 6/6 254 ± 19 6/6 234 ± 12 6/6 232 ± 6
Cattle c-BSE Fr — 6/6 295 ± 12 6/6 265 ± 35 6/6 243 ± 7
Transgenic mice that express the bovine PrP (tgBov) were inoculated intracerebrally (6 to 12 mice, 20 μL per mouse) with 8 sheep or goat (†) atypical
scrapie (AS) isolates originating from 5 different countries, France (Fr), Spain (Sp), Norway (Nor), Italy (It) or Portugal (Po). The AS affected animals
displayed a different PRNP genotype at codons 136, 154, and 171. Some also displayed a F/L dimorphism at codon 141 (*). Cattle classical BSE (c-BSE),
ovine c-BSE (first passage of cattle c-BSE in an ARQ/ARQ sheep by the intracerebral route), and classical scrapie (PS42) isolates were inoculated in the
same mouse model. After first and second passages, clinically affected or asymptomatic mice that had lived for more than 500 d post inoculation were
pooled and used for subsequent passage in the same line. Mice were considered positive when abnormal PrP deposition was detected in the brain.
Incubation periods (in days) are shown as mean ± SD except when less than 50% of the mice were found to be positive. In that case, the incubation
periods of the positive mice are individually presented. NA, not available. Cattle c-BSE transmission in tgBov data from ref. 51. PS42 transmission data
from ref. 15.
‡Abnormal PrP positive and found dead animals (without symptoms).
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Fig. 1. Brain lesion profile and PrPres Western blot profiles in tgBov and tg338 mice inoculated with atypical/Nor98 scrapie (AS) or c-BSE. Groups of mice (n ≥ 6)
that express either ovine VRQ PrP (tg338 mice) or bovine PrP (tgBov mice) were intracerebrally challenged with atypical scrapie isolates (AS) or an ovine
classical BSE isolate (c-BSE). (A) After 2 or 3 iterative passages in each mouse line, a standard lesion profile was established by scoring the vacuolar changes
observed in predefined brain areas. In c-BSE graphs, ●, ovine c-BSE; ○, cattle c-BSE. In AS graphs, ○, AS 1; △, AS 2;▽, AS 3. (B) The accumulation of PK-
resistant PrP (PrPres) in the brain of tgBov mice was established by Western blot using anti-PrP monoclonal antibodies Sha31 (epitope 145-YEDRYYRE-152)
and/or 12B2 (epitope 89-WGQGG-93). The same Western blot PrPres control (classical scrapie isolate) was used on all of the gels labeled as WB control. Cattle
c-BSE and an ovine c-BSE (original isolate and isolate passaged in tgBov) were included as controls. (C) Vacuolar lesions (thalamus level, conventional histology;
hematoxylin-eosin) and abnormal PrP deposition (mesencephalon: tegmentum, immunohistochemistry using 6H4 anti-PrP antibody, epitope 147-DYEDRYYRE-155)
in tgBov mice inoculated with AS3 and cattle BSE. (Scale bars: vacuolar lesions, 25 μm; abnormal PrP deposition, 50 μm.)
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Second passage of the AS isolates in tgBov mice was performed
using either first-passage PrPres-positive brains or pooled PrPres-
negative brains as inoculum. During this process, 7 out of the 8 AS
isolates caused the occurrence of clinical prion disease in a pro-
portion of animals in each group inoculated. On third passage
(available for AS 1, 2, 3, 4, and 7), 100% attack rates and mean
incubation periods that ranged between 235 and 286 dpi were
recorded (Table 1).
At each passage stage, a 3-band PrPres Western blot profile
characterized by a prominent di-glycosylated PrP band was ob-
served in the brains of the clinically positive tgBov mice (Fig. 1B).
Strikingly, the lesion profile (Fig. 1A), the PrPres Western blot
profile (Fig. 1B), and the histopathological lesions (Fig. 1C) in the
brains of AS inoculated tgBov mice were identical to those ob-
served for transmission of c-BSE (sheep or cattle origin) to tgBov
mice. Importantly, the inoculation of one classical scrapie isolate
(PS42) to the same mouse models resulted in the occurrence of a
100% attack rate for prion disease with a short incubation period
in tg338 mice (SI Appendix, Table S1), but no clinical disease or
PrPres accumulation in the brains of tgBov (Table 1).
In order to further characterize the nature of the TSE agent
that propagated in tgBov mice inoculated with the AS isolates,
prions obtained after second passage (isolate AS 2) or third
passage (isolate AS 3) in this mouse line were transmitted (2
iterative passages) to VRQ (tg338) and ARQ (tgARQ) ovine
PrP transgenic mice (Table 2). The incubation periods (Table 2
and SI Appendix, Table S1), the lesion profile (Fig. 2A), and the
PrPres Western blot profile in the brain (Fig. 2B) of tg338 mice
inoculated with tgBov-adapted AS isolates clearly differed from
those observed in the same mouse line inoculated with the
original AS isolates.
No PrPres deposition could be detected in the spleen of tg338
mice inoculated with the original AS isolates (Fig. 3A). Conversely,
transmission in tg338 of tgBov-adapted AS isolates was associated
with a PrPres accumulation in the spleen, as was transmission of
ovine and cattle c-BSE (Fig. 3A). PrPres WB profile in the spleen of
tg338 mice that were inoculated with c-BSE and AS isolates pas-
saged in tgBov were identical (Fig. 3B).
Transmission of tgBov-adapted AS isolates in both tg338 and
tgARQ mice resulted in prion incubation periods (Table 2), brain
vacuolar lesion profiles (Fig. 2A), PrPres Western blot profile
patterns (Fig. 2B), and PrPres distribution patterns in the brain
(Fig. 3A) that were similar to c-BSE passaged in tg338 and tgARQ
mice. Collectively, these results demonstrate beyond reasonable
doubt that our transmission of AS in a bovine PrP host resulted in
the propagation of the c-BSE agent. Since the bioassays reported
here were performed in 3 independent institutes (located in
France and Spain) that used inoculum prepared by 5 distinct
laboratories, we exclude the possibility of a cross-contamination
of the original AS isolates by the c-BSE agent.
Two hypotheses could explain the emergence of the c-BSE
agent in tgBov mice after their inoculation with AS isolates.
First, c-BSE prions could be present at a low level in the original
AS isolates. The high sensitivity of tgBov mice for detection of
the c-BSE agent could allow this potentially low level of bovine
prions to be identified during passage of the original AS isolates
in the bovine PrP host. Alternatively, the occurrence of c-BSE in
AS-inoculated tgBov mice could result from a mutation of AS
strain properties triggered by passage across the bovine trans-
mission barrier for this particular ovine prion strain.
In order to explore the origin of the c-BSE agent observed in
tgBov mice inoculated with AS, we employed in vitro protein
misfolding cyclic amplification (PMCA), a methodology that
mimics prion replication in vitro, but in an accelerated form,
allowing amplification of minute amounts of PrPSc and prion
infectivity (27). In PMCA, a PrPC-containing substrate is com-
bined with a seed that contains PrPSc. Following repeated cycles
of incubation and sonication, the amount of PrPSc increases.
PMCA has been previously reported to amplify the c-BSE agent
with great efficacy using either tgARQ or tgBov mouse brain
homogenate as substrate (28). Using this protocol, 2 (tgARQ sub-
strate) or 3 (tgBov substrate) amplification rounds were suffi-
cient to reach the detection limit for c-BSE prion seeding activity
(SI Appendix, Fig. S2). The level of prion infectivity and prion
seeding activity of a reference sheep-passaged c-BSE isolate
were endpoint-titrated by both bioassays in tgBov mice and
PMCA, respectively (SI Appendix, Table S2). The infectious
prion titer of the sheep-passaged c-BSE isolate was ∼107.2 LD50/g
IC in tgBov mice. The prion seeding titer (SA50) was estimated
to be ∼1011.1 SA50/g using tgARQ mouse tissue as substrate and
1011.05 SA50/g using tgBov mouse tissue as substrate. Considering
the fact that mice were inoculated using 20 μL of sample and the
PMCA reactions were seeded using 5 μL of the same sample, the
PMCA can be considered to be about 1,500 fold more sensitive
than the bioassay in tgBov. This also means that 1 c-BSE LD50 in
tgBov mice corresponds to ∼1,500 SA50 assessed by PMCA.
In addition to its high sensitivity, in vitro PMCA can reproduce,
at least partly, the transmission barrier phenomenon observed
during the in vivo prion bioassay (29). Therefore, amplification of
prion seeding activity in AS isolates by PMCA using tgBov mouse
tissue as substrate offered an opportunity to characterize the po-
tential impact of the bovine transmission barrier on AS strain
properties.
The AS isolates that were originally transmitted to tgBov mice
(except AS8) and 18 additional AS isolates (originating from
Norway, France, and Portugal) were subjected to PMCA (Table 3).
Each AS isolate was used to seed reactions containing either
Table 2. Inoculation of atypical scrapie adapted in tgBov and c-BSE isolates in ovine PrP expressing mouse models (tg338 and tgARQ)
Tg338 TgARQ
Isolates First passage Second passage First passage Second passage
Identifiant Origin
Positive
mice
Incubation,
mean ± SD
Positive
mice
Incubation,
mean ± SD
Positive
mice
Incubation,
mean ± SD
Positive
mice
Incubation,
mean± SD
AS 2 Second pass in TgBov 6/6* >650 6/6 617 ± 75 6/6 350 ± 9 6/6 260 ± 3
AS 3 Third pass in TgBov 6/6* >650 6/6 672 ± 83 6/6 354 ± 21 6/6 257 ± 2
Ovine c-BSE Second pass in TgBov 6/6* >750 6/6 653 ± 32 6/6 270 ± 12 6/6 259 ± 4
Cattle c-BSE Cattle 6/6* >700 6/6 682 ± 52 6/6 321 ± 16 6/6 263 ± 7
Transgenic mice that express the VRQ (tg338) or ARQ (tgARQ) variants of ovine PrP were inoculated intracerebrally (6 mice, 20 μL per mouse) with atypical
scrapie isolates or ovine c-BSE isolate that had previously been adapted in tgBov (2 iterative passages). Cattle BSE was also included as control. After first
passage, clinically affected or asymptomatic mice that had lived for more than 500 d post inoculation were pooled and used for second passage in the same
line. Mice were considered positive when abnormal PrP deposition was detected in the brain. Incubation periods (in days) are shown as mean ± SD.
*Abnormal PrP positive and found dead animals (without symptoms).
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bovine PrP or ovine ARQ PrP substrate (10 to 18 replicates per
substrate). After amplification, PrPres was detected by Western
blot in a low proportion of the reactions seeded, with 19 out of
the 25 AS isolates for tgBov and tgARQ combined (Table 3). In
most instances, a similar proportion of PrPres-positive PMCA
reactions were observed when either bovine PrP or ovine ARQ
PrP was used as substrate. However, in some cases (n = 3), a low
number of PrPres-positive reactions were observed when bovine
PrP was used as substrate (in the case of AS 10) or when ovine
ARQ PrP was used as substrate (in the cases of AS 9 and AS 25).
Whatever combination of AS isolate and substrate PrP was used,
the PrPres Western blot profile in PMCA-positive reaction prod-
ucts and its reactivity with 12B2 antibody were indistinguishable
from those observed for PMCA reaction products seeded with
Fig. 2. Brain lesion profile and PrPres Western blot in the brain of tgARQ and tg338 mice inoculated with AS scrapie adapted in tgBov. Groups of mice (n ≥ 6)
that express ovine VRQ PrP (tg338 mice) or ovine ARQ PrP (tgARQ mice) were intracerebrally challenged with atypical scrapie isolates (AS) or an ovine c-BSE
isolate that had previously been adapted (2 iterative passages) in tgBov mice. (A) After 2 iterative passages in each mouse line, a standard lesion profile was
established by scoring the vacuolar changes observed in predefined brain areas. In AS graphs,△, AS 2;▽, AS 3. (B) The Western blot profile of PK-resistant
PrP (PrPres) in the original AS isolates and in the brain of inoculated mice was established by Western blot using anti PrP monoclonal antibody Sha31 (epitope
145-YEDRYYRE-152). The same Western blot PrPres control (classical scrapie isolate) was used on all of the gels labeled as WB control.
Huor et al. PNAS | December 26, 2019 | vol. 116 | no. 52 | 26857
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authentic ovine c-BSE prions (Fig. 4). No PrPres was observed in
PMCA reactions that were unseeded (n = 120) or in those reac-
tions seeded (n = 60) with prion-free sheep brain homogenate
(representative samples shown in Fig. 4). It should be noted that
the PrP amino sequence was 100% homologous between certain
AS isolates (AS 5, AS 26) and the ovine PrP substrate (tgARQ)
used in PMCA reactions. Therefore, in vitro amplification of
c-BSE prions in PMCA reactions seeded with these AS isolates using
ovine ARQ PrP as substrate cannot be a consequence of mutation
of prion strain properties triggered by a transmission barrier.
Taken together, the tgBov mouse bioassay and PMCA results
strongly support the view that a low level of c-BSE prions was
initially present in at least 21 out of the 26 AS isolates tested.
To further clarify the origin of the c-BSE agent detected in AS
isolates, 2 of these isolates (AS 25 and AS 26) were endpoint-
titrated in tg338 mice (1/10 dilution series, 6 or 7 tg338 mice in-
oculated per dilution). For both isolates, the last positive trans-
missions were observed in mice that received a 10−6 log10 dilution of
the original 10% w/vol brain material (SI Appendix, Table S3). The
brains of these endpoint-titration tg338 mice were subsequently
subjected to PMCA. Irrespective of the substrate used for
PMCA, either bovine or ovine ARQ PrP, PrPres was observed in
a similar proportion of the PMCA reactions seeded with either
the original AS isolates or AS isolates passaged in tg338 mice
(Table 4). The PrPres Western blot profile observed in all of the
PMCA-positive reactions was identical to that seen in reactions
seeded with authentic c-BSE prions (Fig. 5). PMCA reactions
seeded with brain homogenate prepared from age-matched
noninoculated tg338 mice remained PrPres-negative (Table 4
and Fig. 5).
Considering the level of c-BSE seeding activity originally pre-
sent in isolates AS 25 and AS 26 (less than 100 SA50/mL; Table 4),
there is an extremely low level of probability that one of the
6 tg338 mice inoculated with 20 μL of a 10−6 diluted AS isolate
(<2 10−6 SA50 per dose of inoculum) could be exposed to 1 infectious
dose of c-BSE agent (1 c-BSE LD50 is ∼1,500 SA50). Conse-
quently, the presence of c-BSE prion seeding activity in the brains
of tg338 mice inoculated with a 10−6 log10 dilution of original AS
isolate implies that a low titer of c-BSE prions was generated
during the propagation of ovine AS prions in a host that expressed
ovine PrP, namely tg338 mice.
Discussion
The mechanism(s) that lead to an alteration in the phenotype of
prion strains as these transmissible entities undergo transmission
between different host species remain uncertain. This is despite
the identification that differences in amino acid sequence between
host PrPC and donor PrPSc, together with prion strain identity, are
principal determinants of the transmission barrier (9, 10). Based
on the concept that conformation of PrPSc molecules/aggregates
encode prion strain information (2, 4, 5, 30, 31), at least 2 non-
exclusive hypotheses, “deformed templating” (32, 33) and the
“conformational selection model” (32–35), have been proposed to
explain the mutation of prion strains.
The deformed templating hypothesis postulates that a prion
strain replicates as a clone of PrPSc molecules/aggregates. When
confronted by a transmission barrier that does not allow clonal
prion replication, the propagation process is modified so that “al-
tered” PrPSc structural variants are generated in an attempt to
convert the new host PrPC. While the majority of these presumably
fail to replicate efficiently in the new host, variants eventually
emerge that are successful and adapt to the new PrP environment
through multiple trial-and-error replication events. In this de-
formed templating model, confrontation of the transmission bar-
rier serves as the triggering event that initiates the generation of
new prion variant(s) and as a filter for their selection (35).
The conformational selection model proposes that a prion strain
naturally propagates in its host as an ensemble of PrPSc conformers
dominated by a stable energetically favorable conformation re-
sponsible for the observed prion strain phenotype. Furthermore,
this model predicts that the number of stable PrPSc conformers is
limited for each PrP amino acid sequence, which would explain the
existence of a finite number of stable prion strains that can prop-
agate in a given species. It is further proposed that, during trans-
mission of a prion strain to a new host, one of the less dominant
PrPSc conformers of those present in the ensemble is selected with
a resultant change, or mutation, in the properties of the newly
propagating prion strain. In the conformational selection model,
the transmission barrier acts simply as a selective filter for new
prion variants, and ease of permeation of the barrier results from
the extent of overlap of PrPSc conformers that exist between the
interacting species (32, 33).
Our data reported here showed that c-BSE prions are present
as a minor variant in natural isolates of ovine AS. In addition,
transmission of ovine AS to bovine PrP mice demonstrated that
c-BSE can emerge during these transmissions as the dominant
prion strain. These results provide a cogent argument in favor of
Fig. 3. Brain and spleen PrPres accumulation in tg338 mice inoculated with AS
scrapie adapted in tgBov. Groups of mice (n ≥ 6) that express ovine VRQ PrP
(tg338 mice) were intracerebrally challenged with atypical scrapie isolates (AS)
and AS that had previously been adapted (2 iterative passages) in tgBov mice.
In parallel, cattle c-BSE isolate and ovine BSE isolate (adapted in tgBov) were
transmitted (2 iterative passages) in tg338 mice. (A) In tg338 mice (second
passage), the PrPres distribution pattern in the brain (thalamic coronal section)
and in the spleen was established by paraffin-embedded tissue blot using anti-
PrP monoclonal antibody Sha31 (epitope 145-YEDRYYRE-152). (Scale bars:
brain, 160 μm; spleen, 100 μm.) (B) The Western blot profile of PK-resistant PrP
(PrPres) in the spleen of tg338 mice (second passage) inoculated with AS iso-
lates and AS isolates passaged in tgBov and c-BSE (cattle and ovine origin) was
established using anti-PrP monoclonal antibody Sha31.
26858 | www.pnas.org/cgi/doi/10.1073/pnas.1915737116 Huor et al.
D
ow
nl
oa
de
d 
at
 U
NI
V 
DE
 Z
AR
AG
O
ZA
 #
62
87
16
41
 o
n 
Ja
nu
ar
y 
24
, 2
02
0 
the conformational selection model as the mechanism for prion
strain mutation during interspecies prion transmission. This
would be expected to occur by selection of a preexisting PrPSc
variant in AS isolates, one best suited to the new replicative
environment. Within this conceptual framework, the occurrence
of prion strain mutation is dependent upon the particular rep-
ertoire of PrPSc variants associated with distinct prion strains.
This notion is supported by our observation that c-BSE prions
emerged during serial transmission of ovine AS in tgBov mice
but not from serial passage of classical scrapie in the same mouse
line [Table 1 and Cassard et al. (15)].
The diversity of prion strains that exist in small ruminants re-
mains undefined, although it is established that at least 5 different
natural ovine prion strains exist, including AS (6, 36–39).
According to the conformational selection model, each of these
different ovine prion strains is associated with a unique and
stable PrPSc conformer and a distinct set of minor variants. The
tgBov mouse line has previously been reported to support the
propagation of a variety of natural ovine prions, of which several
displayed significantly shorter incubation periods than c-BSE
(15). Strikingly, in our experiments, the diversity of prion vari-
ants in the AS isolates (7 different cases) revealed by the serial
passage in tgBov was restricted to the c-BSE agent (Table 1).
This consistent emergence of a single prion strain argues against
the view that AS prion replication in sheep can randomly gen-
erate all of the existing stable PrPSc variants associated with a
particular ovine PrPC amino acid sequence. Instead, our data
support the view that individual prion strains are associated with
a restricted repertoire of stable PrPSc variants in a given host.
Whether AS is unique in its ability to generate c-BSE prion
particles during its replication process remains to be established.
Classical BSE was first recognized in 1984 and 1985 as a novel
prion disease affecting cattle in the United Kingdom (40). Epi-
demiological data clearly established that the number of cases of
c-BSE was amplified by the recycling of infected animal carcasses
into cattle feed in the form of meat and bone meal (MBM) (41).
Since bovine prion disease had not been recognized in cattle
prior to the c-BSE epizootic and the disease is apparently non-
contagious between cattle, several hypotheses were proposed to
explain its emergence. These range from the spontaneous occurrence
Table 3. Protein Misfolding Cyclic Amplification seeding activity
in atypical scrapie isolates
Isolates PMCA positive reactions
Identifiant Origin Genotype TgBov substrate TgARQ substrate
AS 1 Fr ARQ*/ARQ 3/12 5/12
AS 2 Sp ARR/ARQ 2/12 3/12
AS 3 Sp ARQ/ARH 3/12 4/18
AS 4 No ARQ*/AFRQ 12/12 9/12
AS 5 Sp ARQ/ARQ 4/12 3/12
AS 6 Sp ARQ/ARH 5/12 1/12
AS 7 It ARQ/AHQ 1/12 2/12
AS 8 Po ARQ/ARQ ND ND
AS 9 Nor ARR/ARQ 0/12 2/10
AS 10 — ARQ*/AHQ 1/12 0/10
AS 11 — AHQ/ARQ 3/12 7/12
AS 12 — ARR/ARQ 0/12 0/12
AS 13 — ARR/AHQ 0/12 0/12
AS 14 — ARQ/AHQ 1/12 1/12
AS 15 — ARR/ARR 3/12 1/12
AS 16 — ARR/AHQ 1/12 3/10
AS 17 — ARQ*/AHQ 1/12 1/10
AS 18 — ARQ*/AHQ 0/12 0/10
AS 19 Po ARR/ARR 0/12 0/12
AS 20 — ARR/AHQ 3/12 1/12
AS 21 — ARR/ARR 0/12 0/10
AS 22 — ARQ*/AHQ 0/12 0/12
AS 23 — ARQ*/ARQ 1/12 1/12
AS 24 — ARQ*/ARQ 2/12 4/12
AS 25 Fr AHQ/AHQ 0/12 1/12
AS 26 — ARQ/ARQ 1/12 1/12
TSE free sheep — ARQ/ARQ 0/12 0/12
Unseeded — — 0/120 0/120
Twenty-six AS scrapie cases (1/50 diluted 10% brain homogenates)
originating from 5 different countries (France [Fr], Spain [Sp], Italy [It],
Portugal [Po] and Norway [Nor]) were used to seed PMCA reactions (5 μL of
seed per reaction). The AS affected animals displayed different Prnp geno-
types at codons 136, 154, and 171. Two different PMCA substrates were
used. The first one was prepared using brains from transgenic mice
overexpressing the ARQ variant of the sheep prion protein (tgARQ). The
second was prepared using brains from transgenic mice overexpressing the
bovine prion protein (tgBov). For each isolate and substrate, 10 to 18 indi-
vidual replicates were tested. Reactions were subjected to 3 amplification
rounds. After each round, reaction products (1 volume) were mixed with
fresh substrate (9 volumes) to seed the following round. PMCA reaction
products (third amplification round) were analyzed by Western blot for
the presence of PrPres. The number of PrPres Western blot positive reac-
tions/total number of reactions are reported. Unseeded reactions and reac-
tions seeded with brain homogenate prepared from a TSE-free sheep were
included as specificity controls. ND, not done.
*F/L dimorphism displayed at codon 141.
Fig. 4. PrPres detection in PMCA reactions seeded with atypical/Nor98 scrapie
isolates. Protein misfolding cyclic amplification (PMCA) reactions were seeded
with atypical/Nor98 scrapie (AS) isolates (1/50 diluted 10% brain homogenate)
that had been identified in 5 European countries (Table 3). PMCA reactions
seeded with brain homogenate from a TSE-free sheep (originating from New
Zealand) and unseeded PMCA reactions were included as specificity controls.
PMCA substrate consisted of brain homogenate from either bovine PrP (tgBov)
or ovine PrP (tgARQ) mice. PMCA reactions were subjected to 3 (tgARQ sub-
strate) or 4 (tgBov substrate) amplification rounds, each comprising 96 cycles
(10 s sonication, 14 min and 50 s incubation at 39.5 °C) in a Qsonica700 device.
The PMCA reactions were analyzed by Western blot for the presence of ab-
normal PK-resistant PrP (PrPres) using anti-PrP monoclonal antibodies Sha31
(epitope 145-YEDRYYRE-152) and/or 12B2 (epitope 89-WGQGG-93). Each
Western blot included a classical scrapie isolate (labeled as WB control) and an
ovine c-BSE isolate as controls.
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of c-BSE in cattle to the passage and adaptation of a prion originating
from another species (42, 43). Our studies here that show the pres-
ence of c-BSE prions in AS isolates, combined with the demon-
strated presence of AS in the United Kingdom long before the
appearance of the c-BSE epizootic in cattle, suggests that the
recycling of AS cases in MBM might be a source of bovine prion
disease (20). In addition to its potential role in the initial emer-
gence of c-BSE in cattle, the presence of c-BSE prions in natural
cases of AS has current and direct implications for both the
continued risk of this ovine prion disease to other farmed animals
and for human exposure risks. The distribution of AS cases are
widespread across the world (17–19). A recent retrospective analysis
of surveillance data collected over a period exceeding 10 y in the
European Union (EU) concluded that the prevalence of detected
AS cases has remained relatively stable in the different member
states, with between 2 and 6 positive cases per 10,000 tested animals
per year. This implies that a substantial number of AS-infected ani-
mals could enter either the animal or human food chain each year
(44, 45), and each case represents a potential source of exposure to
the c-BSE agent for farmed animals (MBM derived from rendered
small ruminants) and human consumers (consumption of healthy
slaughtered animals), respectively. The epidemiological features of
AS within the EU is likely to reflect the situation of the disease in
other countries that breed and maintain small ruminants.
In Europe, the c-BSE crisis and the emergence of vCJD resulted
in the implementation of a strong and coherent policy (EU regu-
lation 999/2001) aimed at control and eradication of this animal
prion disease. The total feed ban on the use of MBM in animal feed
and the systematic retrieval from the food chain of ruminant tissues
that have the potential to contain high levels of prion infectivity, so-
called Specified Risk Material (SRM) measures, were instrumental
for control of c-BSE in cattle and prevention of dietary human
exposure to these bovine prions (46, 47). As a side effect, these
measures also strongly limited the exposure of farmed animals
and human consumers to the other TSE agents circulating in
farmed animal species, including AS.
With the decline of the c-BSE epizootic in cattle and the com-
bined increase in pressure from industry, EU authorities have begun
to consider discontinuing certain TSE control measures. The ab-
rogation of the SRM measures for small ruminants and the partial
reauthorization of the use of processed animal protein, formerly
known as MBM, in animal feed are part of the EU authorities’
agenda. Our observation of the presence of the c-BSE agent in
AS-infected small ruminants suggests that modification of the
TSE control measures could result in an increased risk of ex-
posure to c-BSE prions for both animals and humans. Whether
or not this exposure will result in further c-BSE transmission in
cattle and/or humans remains an open and important question.
Methods
Ethics Statement. All animal experiments were performed in compliance with
institutional and French national guidelines and in accordance with the
European Directives 86/609/EEC and 2010/63/EU. In France, the animal ex-
periments that are part of this study (national registration 01734.01) were
approved by the local ENVT ethics committee. Experiments developed in
CISA-INIA (Madrid, Spain) were approved by the Committee on the Ethics of
Animal Experiments of the Instituto Nacional de Investigación y Tecnología
Agraria y Alimentaria and the General Directorate of the Madrid Commu-
nity Government (permit numbers: CEEA 2009/004 and PROEX 228–16).
Mouse inoculations were performed under anesthesia (isoflurane).
Experiments developed in IRTA-CReSA (Barcelona, Catalonia) involving
animals were approved by the animal experimentation ethics committee of
the Autonomous University of Barcelona (reference number 585–3487) in
agreement with Article 28, sections (a), (b), (c), and (d) of the “Real Decreto
214/1997 de 30 de Julio,” European Directive 86/609/CEE, and the European
Council Guidelines included in the European Convention for the Protection
of Vertebrate Animals used for Experimental and Other Scientific Purposes.
Mice that displayed clinical signs were anesthetized with isoflurane before
sacrifice using CO2 inhalation.
Atypical/Nor98 Scrapie Cases and Control Sheep. Natural atypical scrapie (AS)
cases identified through active or passive surveillance programs were selected
according to their geographical origin (France, Spain, Italy, Norway, and Por-
tugal) and PRNP genotypes (SI Appendix, Table S1 and Table 1). These cases
Table 4. PMCA seeding activity in atypical scrapie passaged in tg338
PMCA seeds PrPres positive PMCA reactions Seeding activity, SA50/mL
Case Origin TgBov substrate TgARQ substrate TgBov substrate TgARQ substrate
AS 25 Sheep 0/12 1/12 0 (0–101.86)* 101.40
First passage in tg338 (neat) Mouse 1 2/12 1/12 101.72 101.40
Second passage in tg338 (neat) Mouse 1 2/12 1/12 101.72 101.40
End-point titration in tg338 (10−6 dilution) Mouse 1 2/12 3/12 101.72 101.92
Mouse 2 1/12 3/12 101.40 101.92
Mouse 3 2/12 2/12 101.72 101.72
AS 26 Sheep 1/12 1/12 101.40 101.40
First passage in tg338 (neat) Mouse 1 2/12 0/12 101.72 0 (0–101.86) *
Second passage in tg338 (neat) Mouse 1 2/12 0/12 101.72 0 (0–101.86) *
End-point titration in tg338 (10−6 dilution) Mouse 1 2/12 1/12 101.72 101.40
Mouse 2 1/12 1/12 101.40 101.40
Noninoculated tg338 Mouse 1 0/12 0/12 — —
Mouse 2 0/12 0/12 — —
Mouse 3 0/12 0/12 — —
Two sheep atypical scrapie (AS) isolates were selected. The 10% w/vol brain homogenates were inoculated into tg338 mice (2 iterative passages). Groups of
6 tg338 mice were inoculated intracerebrally with 20 μL of serial 10-fold dilutions of the same homogenates. Transmission was observed in 3 (AS 25) and 2 (AS
26) mice inoculated with 10−6 brain homogenate. No transmission was observed at lower dilutions. PMCA reactions (12 replicates) were seeded with 1/50
diluted brain homogenate (10% w/vol) from 1) the original sheep, 2) the second passage tg338 mice (pool of brains), and 3) individual brain from positive
tg338 in the endpoint titration experiment. Brain homogenates (10% w/vol) from age-matched, noninoculated tg338 mice were also used as seeds (1/50
diluted). Two different PMCA substrates were used. The first one was prepared using brains from transgenic mice overexpressing the ARQ variant of the
sheep prion protein. The second was prepared using brains from transgenic mice overexpressing the bovine prion protein (tgBov). Reactions were subjected
to up to 4 amplification rounds. After each round, reaction products (1 volume) were mixed with fresh substrate (9 volumes) to seed the following round.
PMCA reaction products were analyzed by Western blot for the presence of PrPres. The number of PrPres Western blot-positive reactions/total number of
reactions are reported. Seeding activity titers were estimated using the Spearman–Karber’s limiting dilution titration method (most likely value) or, when no
positive reaction was observed, by the Poisson’s probabilistic model. Titers are given as the number of PMCA SA50 per milliliter of 10% brain homogenate.
*Most likely value and IC 95% as described by Brown et al. (66).
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have been originally classified as AS by TSE national reference laboratories in
each country. All of the cases corresponded to sheep except the AS 7 case (goat).
In all cases, PrPgenotypewas checkedby sequencingexon3of thePRNPgeneas
previously described (48). The polymorphisms at codons 136 (A/V), 154 (H/R), and
171 (R/Q/H), which have been demonstrated to strongly influence the susceptibility
to TSE in sheep, are indicated (49). Additionally, the presence of a phenylalanine at
codon 141 (F/L), which has been shown to impact on the susceptibility to atypical/
Nor98 scrapie, are also indicated (Tables 1 and 4) (23, 48). Brain material collected
in TSE-free Poll–Dorset sheep (APHA) was used as control (50).
c-BSE Isolates. Cattle and ovine classical BSE (c-BSE) isolates were used as
control. The cattle c-BSE isolate was a natural case originating from France.
This isolate was used in previous studies aimed at the characterization of
c-BSE strain properties through transmission to mice overexpressing the PrP
sequence of various host species (51). The ovine c-BSE isolate was obtained by
the intracerebral inoculation of the same cattle c-BSE isolate in ARQ/ARQ
TSE-free sheep (first passage) as described in Andréoletti et al., 2004 (50).
Mouse Bioassays. Bioassays were carried out using mice expressing bovine PrP
(tgBov/tg110) (52, 53) and/or mice expressing ovine ARQ (tgARQ) (54) or VRQ
(tg338) PrP (55).
Groups of 6- to 10-wk-old female mice (n ≥ 6) were anesthetized and in-
oculated with 20 μL of a 10% tissue homogenate in the right parietal lobe
using a 25-gauge disposable hypodermic needle. Mice were observed daily, and
their neurological status was assessed weekly. When clinically progressive TSE
disease was evident, the animals were euthanized and their brains harvested.
Half of the brain was fixed by immersion in 10% formol saline and the other
half was frozen at −20 °C. Tissues from animals found dead were frozen (no
formalin fixation). In animals where no clinical signs were observed, mice were
killed at the end of their natural lifespan (650 to 750 d). In those cases, in-
cubation periods reported in Tables 1 and 2 as >650 dpi corresponded to the
survival time observed in at least 3 out of the 6 mice.
PMCA Amplification. Brains from tgBov, tgARQ, and tg338 mice were used to
prepare the PMCA substrates. PMCA was performed as previously described
(28, 56). Briefly, PMCA reactions (50 μL final volume) were seeded with 5 μL
of sample to be tested. PMCA reactions were then subjected to 3 amplifi-
cation rounds, each comprising 96 cycles (10 s sonication, 14 min and 50 s
incubation at 39.5 °C) in a Qsonica700 device. After each round, reaction
products (1 volume) were mixed with fresh substrate (9 volumes) to seed the
following round. The PMCA reaction products were analyzed by Western
blot for the presence of PK-resistant PrP. Each WB line was loaded with the
equivalent of 20 μL of PK-digested PMCA product. Each PMCA run included a
reference ovine BSE sample (10% brain homogenate) as a control for the
amplification efficiency. Unseeded controls (2 unseeded controls for 8
seeded reactions) were also included in each run.
Western Blot Detection of Abnormal PrP. PK-resistant abnormal PrP (PrPres)
extraction and Western blot were performed as previously described (57).
Immunodetection was performed using 2 different PrP-specific monoclonal
antibodies, Sha31 (1 μg/mL) (58) and 12B2 (4 μg/mL) (59), which recognize
the amino acid sequences YEDRYYRE (145–152) and WGQGG (89–93),
respectively (60).
Paraffin-Embedded Tissue Blot. Paraffin-embedded brain tissue from inocu-
lated mice was analyzed as previously described (61–63).
Lesion Profiling and Abnormal PrP Immunohistochemistry. Vacuolar brain le-
sion profiles were established following the method described by Fraser et al.
(64). In situ PrPSc immune labeling was performed as previously described
(63) using 6H4 anti-PrP antibody (epitope: 147DYEDRYYRE155 of the bovine
PrP concentration 3 μg/mL).
Infectious and Seeding Activity Titer Estimates. A series of 1/10 dilutions of a
reference 10% w/vol brainstem from an ovine-BSE (ARQ/ARQ) isolate and 2 AS
isolates (AS 25 and AS 26) were prepared. Successive 1/10 dilutions of brain
homogenate were inoculated intracerebrally (20 μL) into tgBov or tg338 mice
(n = 6 per inoculum). Dilutions of the same c-BSE isolate were used to seed
PMCA reactions that used brain tissue from either bovine PrP (tgBov mice) or
ovine ARQ PrP (tgARQ mice) as substrate. Twelve individual replicates of each
sample dilution were tested. Reactions were then subjected to 3 amplification
rounds. PMCA reaction products (third amplification round) were analyzed by
Western blot for the presence of PrPres. The titer of prion seeding activity was
estimated by the Spearman–Kärber’s method (65).
For AS and AS passaged in tg338 isolates (10% brain homogenate), 1/50
diluted material was used to seed 12 individual reactions (tgBov or tgARQ
substrates). After 3 amplification rounds, the number of PrPres Western
blot-positive reactions per total number of reactions was established.
These ratios were used to estimate seeding activity titers (SA/μL of 10%
brain homogenate) by the limiting dilution titration method (application
of Poisson’s probabilistic model) described by Brown et al. (66) or by
Spearman–Kärber’s method. According to Fisher et al. (67) and as pre-
viously used for prion infectivity comparisons (68), 1 SA50 was considered
to be equivalent to 0.693 SA.
Data Availability. All data are available in the manuscript and SI Appendix.
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Fig. 5. PMCA seeding activity detection in 2 bioassay endpoint-titrated
atypical/Nor98 isolates. Two atypical/Nor98 isolates, AS 25 and AS 26 (Ta-
ble 3), were endpoint-titrated in tg338 mice (1/10 dilution series, 6 tg338
mice per dilution). For both isolates, the last positive transmissions were
observed in mice that received a 10−6 dilution of the original 10% w/vol
brain material (SI Appendix, Table S3). The original AS isolates and the brains
of clinically affected mice inoculated with neat and 10−6 diluted isolates
were used to seed PMCA reactions that either used tgARQ or tgBov as
substrate. PMCA reactions seeded with age-matched inoculated tg338 mice
and unseeded reactions were included as specificity controls. Reactions were
subjected to 3 (tgARQ substrate) or 4 (tgBov substrate) amplification rounds,
each comprising 96 cycles (10 s sonication, 14 min and 50 s incubation at
39.5 °C) in a Qsonica700 device. The PMCA reactions were analyzed by
Western blot for the presence of abnormal PK-resistant PrP (PrPres) using the
Sha31 (epitope 145-YEDRYYRE-152) and/or the 12B2 (89-WGQGG-93) anti-
PrP antibodies. Each Western blot included a classical scrapie isolate (labeled
as WB control) and an ovine c-BSE isolate as controls.
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